

11 April 2017

ANTEO PROGRESSES SECOND BATTERY PATENT TO PCT

Highlights

- **Anteo further strengthens its patent position in the fields of Li-ion batteries and other energy related applications.**
- **Anteo continues to advance the strategy for the commercialisation of these energy related assets.**

Last year, Anteo progressed its first patent application for batteries and other energy related opportunities to PCT phase. At that time, Anteo initiated other patent applications to further strengthen its proprietary position in this space.

Anteo Diagnostics is now pleased to announce that a second PCT application, “Conductive Composites” was filed on 29 March, 2017. Anteo’s first patent in this energy space was directed at coatings that helped prevent fragmentation of new high performance battery materials under cycling stress. This second patent relates to the maintenance of tight conductive interfaces between the components that make up the active materials in the battery. In this context, Anteo coatings act like a mixing enhancer to form a good homogenous mixture of battery active materials. The patent also covers the adhesion of such active materials to the current collector.

Anteo believes the above three attributes of its binders/coatings, when acting synergistically, can provide attractive cost effective solutions for the development of high capacity, fast charging batteries with long cycle lives. The company continues on its commercialization plans and, as part of the process, is progressing its research activities in a manner that will clearly delineate how each particular attribute comes together to achieve the most optimum outcome.

Anteo Group CEO Dr. Jef Vangenechten commented “Anteo’s IP position in batteries is significantly improved by taking this patent application to PCT, with each patent supporting the other.

The body of work undertaken to exemplify this patent and justify taking it to PCT has significant commercial implications. Both robustness and uniformity testing of Anteo coatings on internal active particles and current collectors strongly supports earlier research undertaken.

We are pleased to see the data amassed to support these two patents coming together to allow test batteries to be trialled by potential partners in the near future.”

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 countries across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit www.anteodx.com